Understanding Your Options

Peripheral Neuropathy Treatment Options & the Science

Name: Peripheral Neuropathy Treatment Options & the Science
Creator: Sean Flannagan, DPT

Not every neuropathy treatment is designed to do the same thing. Some target pain. Some address underlying causes. Some focus on balance, strength or walking. Others are still emerging. This page helps you understand what each approach is trying to change—and what the evidence actually supports.

The Fit Check helps determine whether a PNRS evaluation or another next step may be appropriate. It does not diagnose neuropathy and does not open a public appointment calendar.

In-person PNRS evaluations in Gilbert and Casa Grande, Arizona • Serving Chandler and the East Valley • Remote and home-based options may be available for appropriate participants

This page provides general education and is not a diagnosis or individualized treatment recommendation. Evidence may apply only to specific neuropathy types, patient populations, devices, protocols or measured outcomes.

The Right Question Is Not Just “Does It Work?”

The more useful questions are about what a treatment was studied for, who it was studied in, and what actually changed.

What type or cause of neuropathy was studied?
What was the treatment trying to change?
Was the measured outcome pain, sensation, balance, strength, walking, nerve conduction or quality of life?
How strong and applicable was the research?
How long did any improvement last?
Does the evidence apply to this individual patient?

The first step is not choosing a treatment. It is understanding what is changing and what should be measured.

How to Read the Evidence Labels

These labels do not rank treatments from good to bad. They describe how confidently a conclusion can be applied to a particular population and outcome.

Guideline-supported for a defined outcome

Supported by guidelines or multiple higher-quality studies for a specific outcome in a defined population. Still applies to particular groups—not every person or every cause of neuropathy.

Supported for selected patients

Evidence supports use in selected patients meeting specific criteria. Not automatically appropriate for every neuropathy type or severity.

Promising or condition-specific

Encouraging findings in certain conditions—often diabetic peripheral neuropathy—but devices, doses and outcomes vary. Larger controlled trials are often needed.

Emerging or mixed

Some studies report positive results and others do not, or the research is small and methodologically limited. May help some people but is not uniformly effective.

Insufficient for broad neuropathy claims

Limited, preliminary or lower-quality evidence. An option may be worth considering in selected situations, but insufficient evidence is not proof that it works.

Evidence strength depends on what outcome was actually studied.

A treatment may have meaningful evidence for pain relief while still having limited or uncertain evidence for restoring sensation, improving balance, changing nerve conduction, or reversing nerve damage.

Evidence from one type of neuropathy cannot automatically be applied to another. Research involving diabetic peripheral neuropathy, chemotherapy-induced neuropathy, focal nerve entrapment and unexplained polyneuropathy may produce very different conclusions.

Five Roles Neuropathy Care May Need to Address

Medical and Cause Management

Neuropathy care may begin with identifying and managing contributors such as diabetes, medication effects, nutritional deficiencies, alcohol exposure, autoimmune disease, kidney disease, chemotherapy, focal nerve compression or other medical conditions. Not every cause is reversible, and some require a physician's ongoing management.

Symptom Management

Medications and other pain-focused interventions may reduce burning, electric, shooting or hypersensitive pain for some patients. Symptom relief can be meaningful even when it does not prove that nerve structure, sensation, balance or walking has changed.

Nutrition and Lifestyle

Glucose management, physical activity, nutrition, sleep, tobacco avoidance, alcohol reduction when relevant, foot protection and correction of verified deficiencies may support overall health and risk management.

Correcting a documented deficiency is different from taking a generic “neuropathy supplement.” Some supplements can be ineffective, interact with medications or become harmful at excessive doses. Excess vitamin B6, for example, can itself contribute to neuropathy.

Rehabilitation

Rehabilitation may address balance, strength, walking, mobility, fall risk, functional confidence and the ability to participate safely in daily life. Improvement in function does not necessarily mean the underlying neuropathy has been reversed.

Adjunctive and Emerging Approaches

Technologies, hands-on care, needling procedures, regenerative products and invasive treatments vary greatly in evidence, risk, cost, regulation and appropriate patient population. An emerging option is not automatically better, and limited evidence is not the same as established evidence.

Daily Participation + Measurement

Meaningful care requires consistent participation and objective reassessment. Different treatments should be measured according to what they are actually intended to change.

How Do TENS, Pulsed Direct Current and Multi-Waveform Electrical Stimulation Differ?

Electrical-stimulation devices can differ in current direction, waveform, frequency, pulse characteristics, intensity, intended use and treatment protocol. Evidence from one device or protocol should not automatically be applied to every electrical-stimulation system.

A treatment may have meaningful evidence for one outcome—such as pain relief—while having limited or uncertain evidence for restoring sensation, improving balance, changing nerve conduction or reversing nerve damage.

Evidence strength depends on the population studied, the exact device and protocol used, and the outcome that was actually measured.

Pulsed Direct Current Compared With Conventional TENS

Condition-Specific Human Evidence

A 2025 randomized, open-label study of 150 adults with diabetic peripheral neuropathy compared a pulsed direct-current foot-stimulation protocol with conventional TENS. Adjusted analyses favored the pulsed-direct-current group on several clinical sensory measures, with differences also observed in selected nerve-conduction outcomes.

Limitation: The study was specific to diabetic peripheral neuropathy, was open-label and did not establish whether observed changes persisted long term. It provides condition-specific human evidence relevant to pulsed direct-current stimulation—one part of the scientific rationale considered within PNRS—but does not establish device-specific outcomes for either technology.

Kostopoulos D, et al. — Open-label comparative study of pulsed direct current and TENS in diabetic peripheral neuropathy (Journal of Diabetes Research, 2025) →

Understanding Different Electrical-Stimulation Waveforms

Narrative Review—Not a Device-Efficacy Trial

A 2025 narrative review coauthored by Dr. Sean Flannagan discusses the characteristics and rehabilitation implications of several electrical-stimulation modalities, including TENS, neuromuscular electrical stimulation, functional electrical stimulation and microcurrent. It provides an educational framework for understanding waveform differences but does not prove that ARPWave or any multi-waveform device is superior for peripheral neuropathy.

Flannagan S, et al. — Narrative review of electrical-stimulation modalities (PubMed, 2025) →

Mechanistic Background: Microcurrent

Laboratory Evidence—Not Clinical Neuropathy Evidence

Laboratory research has examined how certain microcurrent exposures may affect cellular processes such as ATP production and protein synthesis. These findings came from animal tissue under controlled laboratory conditions and should not be interpreted as evidence that ARPWave or FlexDoctor increases ATP by a particular amount in people with neuropathy.

Cheng N, et al. — Effects of electric currents on ATP generation, protein synthesis and membrane transport of rat skin (Clinical Orthopaedics and Related Research, 1982) →

ARPWave Clinical Technology

Cleared Uses and Clinician-Directed Application

ARPWave is a prescription electrical muscle-stimulation technology that may be incorporated when clinically appropriate to support goals such as muscle re-education, increasing local blood circulation, maintaining or increasing range of motion and movement-based rehabilitation. Its role within PNRS is determined by the evaluation and individual clinical plan.

Limitation: FDA clearance for specified powered-muscle-stimulator indications is not the same as FDA approval for treating peripheral neuropathy. Device clearance does not establish that ARPWave reverses nerve damage or produces the outcomes observed with a different pulsed-direct-current device.

FDA 510(k) clearance K093259 — powered muscle stimulator →

FlexDoctor Home Technology

Optional Home Muscle-Conditioning Technology

FlexDoctor is a portable electrical muscle-stimulation device intended for specified muscle-conditioning purposes. It should not be presented as a treatment for neuropathy, an underlying medical condition or injured or ailing muscles. Because peripheral neuropathy may involve reduced sensation, suitability and safe use require individualized review.

Technology Is One Tool. The System Is the Advantage.

Research can help explain what a particular device or protocol has done in a particular study. It cannot determine which problems are affecting an individual person or which intervention is appropriate.

PNRS uses professional evaluation, clinical reasoning, appropriate treatment selection, home participation, functional retraining, tracking and reassessment. Electrical stimulation may be one part of that process, but it does not replace the complete plan.

Understand What Has Changed

Select Appropriate Tools

Build Daily Participation

Measure Function

Adjust the Plan

See whether a professional neuropathy evaluation appears to be an appropriate next step.

Take a deeper guided look at neuropathy treatment categories, evidence, decision-making questions and possible next steps.

Other Neuropathy Treatments You May Encounter

People searching for neuropathy help encounter treatments with very different goals and levels of evidence. The summaries below are intentionally brief. They are designed to help you ask better questions—not to tell you which treatment you personally need.

A. Technology and Neuromodulation

Pulsed Electromagnetic Field Therapy — PEMFEmerging or mixed

What the evidence suggests:

Studies have explored PEMF for neuropathic symptoms, particularly in diabetic peripheral neuropathy, but protocols and findings vary. It should not be presented as a broadly established method for restoring peripheral nerves, sensation, balance or function across all neuropathy types.

PubMed — Effectiveness of PEMF on Peripheral Neuropathy →

Vibration TherapyEmerging or mixed

What the evidence suggests:

Whole-body or localized vibration may influence balance, strength, circulation or sensory input, but the neuropathy literature has been small and methodologically limited. Evidence is not yet strong enough to conclude that vibration reverses diffuse peripheral nerve damage.

PubMed — Whole-body vibration in diabetic peripheral neuropathy →

Red and Near-Infrared Light — PhotobiomodulationPromising or condition-specific

What the evidence suggests:

Photobiomodulation has shown encouraging findings in some diabetic peripheral neuropathy studies, but study designs, devices, wavelengths, doses and outcomes vary. Larger controlled trials are needed before broad conclusions can be made about nerve recovery or long-term functional improvement.

PubMed — Photobiomodulation for diabetic peripheral neuropathy →

Shockwave TherapyPromising or condition-specific

What the evidence suggests:

Shockwave research has examined certain nerve entrapments, pain conditions and diabetic wound applications. Evidence from focal conditions should not be generalized to diffuse polyneuropathy, and shockwave should not be presented as a universally proven nerve-regeneration treatment.

PMC — Shockwave therapy for carpal tunnel syndrome →

Scrambler TherapyEmerging or mixed

What the evidence suggests:

Scrambler therapy has been studied for several neuropathic pain conditions, including chemotherapy-related neuropathy. Some studies report pain improvement, but methods and results vary, and the evidence does not establish restoration of sensation, balance or peripheral nerve structure.

PubMed — Scrambler Therapy for neuropathic pain (scoping review) →

Spinal Cord StimulationSupported for selected patients

What the evidence suggests:

Spinal cord stimulation has evidence for selected patients with refractory painful diabetic neuropathy who have not responded adequately to less invasive care. It is an invasive intervention, and evidence for pain relief should not automatically be interpreted as universal reversal of neuropathy.

PubMed — Spinal cord stimulation for painful diabetic neuropathy →

Hyperbaric Oxygen TherapyEmerging or mixed

What the evidence suggests:

Hyperbaric oxygen has been investigated in diabetic peripheral neuropathy and diabetic wound care. Some studies report changes in nerve-conduction or symptom measures, but limitations and variation in protocols prevent broad conclusions for routine treatment of peripheral neuropathy.

PubMed — Hyperbaric oxygen for diabetic peripheral neuropathy →

Transcutaneous Electrical Nerve Stimulation — TENSGuideline-supported for a defined outcome

What the evidence suggests:

TENS may be considered as a non-drug option for reducing neuropathic pain in some patients. Its evidence is primarily symptom-focused; pain relief does not by itself demonstrate restored sensation, improved balance, changed nerve conduction or reversal of nerve damage.

NCBI Bookshelf — Peripheral neuropathy management overview →

Want the Deeper Research Breakdown?

The Neuropathy Clarity & Next Steps Roadmap™ goes deeper into the major treatment categories—what each treatment is trying to change, what outcomes have actually been studied, and what questions to ask before investing in care.

It is a guided way to understand the evidence and apply the right questions to your own situation—not a substitute for individualized medical care.

B. Needling and Regenerative Approaches

Dry NeedlingEmerging or mixed

What the evidence suggests:

Dry needling may be incorporated when an examination identifies associated muscular pain, mobility limitations or neuromuscular impairments that may benefit from it. Preliminary research is limited, and it is not a proven method for regenerating peripheral nerves or reversing diffuse neuropathy.

PubMed — Dry needling and neurodynamic exercise in idiopathic peripheral neuropathy →

AcupuncturePromising or condition-specific

What the evidence suggests:

Acupuncture may improve pain or symptom measures in some diabetic peripheral neuropathy studies, but reviews note variation in study quality, treatment methods and comparisons. Current evidence should not be generalized to every neuropathy type or interpreted as proof of nerve regeneration.

PubMed — Acupuncture for diabetic peripheral neuropathy →

Platelet-Rich Plasma — PRPPromising or condition-specific

What the evidence suggests:

PRP has been studied more often in focal nerve entrapments, such as carpal tunnel syndrome, than in diffuse peripheral polyneuropathy. Early findings from a focal condition should not be used to claim that PRP broadly restores damaged peripheral nerves.

Reference under clinical review

Stem Cell ProductsInsufficient for broad neuropathy claims

What the evidence suggests:

Cell-based therapies remain investigational for most peripheral neuropathy applications. Laboratory or early clinical research does not establish that commercially marketed stem cell products safely reverse diffuse neuropathy. Patients should verify regulatory status and avoid assuming that “regenerative” means FDA-approved or proven.

FDA — Patient and consumer information about regenerative medicine therapies →

Exosome ProductsInsufficient for broad neuropathy claims

What the evidence suggests:

Exosome products are widely marketed using regenerative language, but broad claims for treating neuropathy are not supported by established clinical evidence. The FDA has warned consumers about unapproved exosome products and reports of serious adverse events.

FDA — Consumer alert on stem cell and exosome products →

C. Hands-on, Supportive and Surgical Care

MassagePromising or condition-specific

What the evidence suggests:

Massage may support comfort, relaxation, mobility and participation for some patients. Small studies have reported symptom-related benefits, but massage has not been established as a stand-alone treatment that reverses diffuse peripheral nerve damage.

PubMed — Foot massage for neuropathic symptoms →

ReflexologyEmerging or mixed

What the evidence suggests:

Reflexology has been studied for pain, quality of life and symptom relief in several populations, including some people with diabetic neuropathy. Results should be interpreted as supportive or symptom-focused and not as proof that reflexology restores damaged peripheral nerves.

PubMed — Systematic review and meta-analysis of reflexology →

Chiropractic and Manual TherapyInsufficient for broad neuropathy claims

What the evidence suggests:

Manual therapy may be appropriate when a patient also has mechanical or musculoskeletal impairments. However, diffuse peripheral neuropathy requires appropriate evaluation and should not automatically be attributed to a spinal, joint or alignment problem.

Reference under clinical review

Surgical Decompression for Confirmed Focal Nerve EntrapmentSupported for selected patients

What the evidence suggests:

Surgical decompression may be appropriate for a confirmed focal nerve entrapment in selected patients. Correctly identifying entrapment is essential, and evidence involving focal compression should not automatically be applied to diffuse peripheral polyneuropathy.

PMC — Nerve decompression when diabetic neuropathy and focal entrapment coexist →

Six Questions to Ask Before Investing in Neuropathy Treatment

What is this treatment trying to change—pain, sensation, balance, strength, walking, nerve conduction or function?
Who was actually studied—people with diabetic neuropathy, chemotherapy-induced neuropathy, focal nerve entrapment or another condition?
What outcome improved, and was that outcome important to the patient?
How strong and consistent is the evidence?
What has not been proven?
How will we measure whether it worked for me?

This is the same standard we believe should be applied to PNRS.

How PNRS Puts the Different Roles Together

CAUSE

PROTECT

RESTORE

RETRAIN

REPEAT

CAUSE

Identify or coordinate care around medical, metabolic, nutritional, medication-related or mechanical contributors when possible.

PROTECT

Support safety, foot protection, nutrition, lifestyle, metabolic health and reduction of avoidable risks.

RESTORE

Use selected symptom-focused, hands-on or adjunctive strategies when appropriate to the individual.

RETRAIN

Address balance, strength, sensory input, mobility, gait and everyday function through individualized rehabilitation.

REPEAT

Build consistent home participation, tracking and reassessment into the process.

PNRS does not assume that one modality will solve every problem. Different components are intended to address different goals, and the individual patient is measured rather than assuming a treatment worked.

PNRS does not claim that every component has the same level of evidence or serves the same purpose. Medical coordination, symptom management, rehabilitation, home participation and selected adjuncts address different parts of the problem. That is why PNRS begins with evaluation and measures the individual rather than assuming one treatment works for everyone.

PNRS Clinical may include clinician-directed treatment such as shockwave, multi-wave direct current stimulation, dry needling and physical therapy or neuromuscular rehabilitation when indicated. Not every PNRS Clinical participant receives every modality.

Learn more about the Peripheral Neuropathy Reset System™ →

Authorship & Clinical Review

Clinically reviewed by Sean Flannagan, PT, DPT

More than two decades of clinical experience

Last reviewed: September 2026

Learn more on the main PNRS page or read the full About Dr. Sean Flannagan page.

Research Explains. Evaluation Clarifies.

Research can explain what a treatment has done in a study. An evaluation helps determine what your symptoms have affected and which options may be appropriate for you.

Prefer to study your options first?

Evidence summaries are educational and are not treatment recommendations. Research findings may apply only to specific neuropathy types, patient populations, devices, treatment protocols or measured outcomes.

References & Further Reading

Medical disclaimer: This page provides general educational information and does not replace individualized medical evaluation, diagnosis or treatment. Results vary. Seek immediate medical care for urgent or rapidly worsening symptoms.

In-person evaluations are provided in Gilbert, Arizona, serving Chandler and the East Valley. PNRS Home may be available to appropriate participants nationwide, subject to clinical appropriateness and applicable professional requirements.

Clinical content reviewed by Sean Flannagan, DPT. Last clinically reviewed: September 2026.